News | May 28, 2021
Bharat Biotech signs MoU with GCVC for COVID Vaccine
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
The company aims to make preventive and specialist healthcare as accessible as everyday retail experiences
Partnership with Duopharma Biotech covers human insulin, insulin glargine and insulin aspart, supporting diabetes care and medicine security in Malaysia
New Centre of Excellence brings advanced robotic platforms and multidisciplinary expertise under one roof to expand access to precision-led minimally invasive surgery
Visakhapatnam-based hospital reaches major milestone in robotic orthopaedics, helping patients across North Andhra Pradesh and Odisha regain mobility through precision-assisted knee replacement procedures.
With this commissioning, Shilpa Medicare joins a very small group of Indian companies capable of offering end-to-end ADC Drug Substance development and manufacturing
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Subscribe To Our Newsletter & Stay Updated
